Albumin for patients with acute large vessel occlusive stroke undergoing endovascular therapy-2 (ARISE-2): protocol for a randomised controlled trial.
Zilin Xu, Yuanyuan Liu, Yanbo Huang...
https://pubmed.ncbi.nlm.nih.gov/42831671/Actively Recruiting
Led by Capital Medical University · Updated on 2026-10-29
1192
Participants Needed
61
Research Sites
23 weeks
Total Duration
Researchers are studying the use of albumin combined with endovascular treatment in patients who have an acute ischemic stroke in the anterior circulation. This trial is a prospective, multicenter, open-label, randomized controlled study aiming to determine the safety and effectiveness of adding albumin to the standard endovascular therapy for this condition. Patients will be selected based on specific criteria including stroke severity and imaging findings. Participants will be randomly assigned to one of two groups one receiving albumin along with endovascular treatment, and the other receiving only the recommended endovascular treatment. Albumin is given as a 25% human albumin intravenous infusion at a dose of 0.5gkg maximum 37.5g once initially and then daily for the next three days. Both groups will also receive acute stroke care and secondary prevention therapies according to current guidelines. During the study, participants will undergo initial imaging tests such as CT or MRI scans to confirm stroke location and exclude hemorrhage, along with laboratory tests and stroke severity assessments including the NIH Stroke Scale and modified Rankin Scale. Vital signs will be monitored, and patients will be followed for 90 days after randomization via telephone to evaluate their recovery and quality of life. The primary outcome is the proportion of patients achieving good functional status or returning to their baseline by 90 days.
CONDITIONS
Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2
C
Chuanjie Wu, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Capital Medical University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 4 days of albumin infusion with endovascular therapy on day 1
Participants receive either albumin combined with endovascular treatment or endovascular treatment alone according to random assignment.
Initial imaging and assessments at baseline; follow-up assessments per protocol
Duration - 90 days
Participants are followed up for 90 days after randomization to assess recovery and quality of life through telephone interviews and clinical evaluations.
Telephone follow-up at 90 days post-randomization
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Zilin Xu, Yuanyuan Liu, Yanbo Huang...
https://pubmed.ncbi.nlm.nih.gov/42831671/Capital Medical University
Lead Sponsor